6533b870fe1ef96bd12d0684

RESEARCH PRODUCT

68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter

subject

description

Abstract Purpose Bone metastases are a serious aggravation for patients suffering from cancer. Therefore, early recognition of bone metastases is of great interest for further treatment of patients. Bisphosphonates are widely used for scintigraphy of bone lesions with 99m Tc. Using the 68 Ge/ 68 Ga generator together with a macroyclic bisphosphonate a comparable PET-tracer comes into focus. Procedures The bisphosphonate DOTA-conjugated ligand BPAMD was labelled with 68 Ga. [ 68 Ga]BPAMD was evaluated in vitro concerning binding to hydroxyapatite and stability. The tracer's in vivo accumulation was determined on healthy rats and bone metastases bearing animals by μ-PET. Results BPAMD was labelled efficiently with 68 Ga after 10min at 100°C. [ 68 Ga]BPAMD showed high in vitro stability within 3h and high binding to hydroxyapatite. Consequently, μ-PET experiments revealed high accumulation of [ 68 Ga]BPAMD in regions of pronounced remodelling activity like bone metastases. Conclusions 68 Ga BPAMD reveals great potential for diagnosis of bone metastases via PET/CT. The straight forward 68 Ga-labelling could be transferred to a kit-preparation of a cyclotron-independent PET tracer instantaneously available in many clinical sites using the 68 Ge/ 68 Ga generator.